Streetbeat News

Revenues

BB

EVAX

GETR

MMAT

NFLX

Netflix, Inc. (NASDAQ:NFLX) shares rose by 10.2% in pre-market trading after reporting Q4 revenue of $8.83 billion, surpassing the consensus estimate of $8.72 billion, despite missing EPS estimates. The company added 13.12 million net paid subscribers in Q4. Other stocks also moved in pre-market trading, with notable gainers including Getaround, Inc. (NYSE:GETR), Evaxion Biotech A/S (NASDAQ:EVAX), and Zoomcar Holdings, Inc. (NASDAQ:ZCAR), while Meta Materials Inc. (NASDAQ:MMAT) and BlackBerry Limited (NYSE:BB) were among the losers.

Portfolio Pulse from Avi Kapoor

January 24, 2024 | 1:14 pm

PRSO

Peraso Inc. (NASDAQ:PRSO) has received its first commercial order for the Perspectus mmWave antenna modules, designed to support the DUNE platform in dense urban environments. The order validates Peraso's concept and its ability to deliver affordable gigabit wireless to underserved markets. The PRM2144X module, with its 128 element phased array antenna, is tailored for dense urban areas and also benefits suburban and rural deployments. Peraso's technology aims to address broadband infrastructure challenges and expand internet access in congested networks using its license-free 60 GHz network solutions.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 1:13 pm

PGR

Progressive Corporation reported a 21% year-over-year increase in net premiums written for Q4, totaling $15.1298 billion.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 1:13 pm

TWST

Twist Bioscience Corporation (NASDAQ:TWST) has expanded its Twist Express Genes service to include larger DNA preparations up to 1 milligram. The service, which offers a turnaround starting at five business days, now covers midiprep and maxiprep DNA preparations. This expansion enables researchers in various fields to access rapid gene synthesis at all scales, facilitating large scale experimentation and accelerating research and discoveries. Twist leverages its silicon-based DNA synthesis platform and the expanded layout of its Wilsonville facility to deliver these services with dynamic pricing.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 1:10 pm

VCIG

VCI Global Limited (NASDAQ:VCIG) through its subsidiary V Capital Real Estate Sdn Bhd, has acquired leasing rights for land and Impiana Private Villas Kata Noi in Phuket, Thailand. The acquisition includes 11 villas with potential for future expansion. Thailand's economic growth is expected to rise, with tourism playing a significant role. The country's hospitality industry is projected to reach USD$19 billion by 2028, and VCI Global views this as a strategic investment in line with their Southeast Asia hospitality sector expansion strategy.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 1:04 pm

DHR

Analyst ratings for Danaher (NYSE:DHR) show a mix of opinions, with recent actions including both raised and lowered price targets. The average 12-month price target is now $242.5, up from $235.00. Danaher's financials indicate a decline in revenue growth, a strong net margin, and efficient use of assets, but it lags behind its peers in revenue growth rate. The company has a low debt-to-equity ratio, suggesting prudent financial management.

Portfolio Pulse from Benzinga Insights

January 24, 2024 | 1:00 pm

GM

Nine analysts have provided diverse opinions on General Motors (NYSE:GM) over the last three months, with ratings ranging from bullish to indifferent. The average 12-month price target is $46.26, down from $48.00. Analysts from firms like Citigroup and Mizuho have raised their price targets, while others like Wedbush and Morgan Stanley have lowered theirs. General Motors regained its U.S. market share leader position in 2022 and has shown a positive revenue trend with a growth rate of 5.35% as of September 30, 2023. However, the company's debt-to-equity ratio is higher than the industry average, indicating potential financial risk.

Portfolio Pulse from Benzinga Insights

January 24, 2024 | 1:00 pm

BIIB

Biogen (NASDAQ:BIIB) has received mixed analyst ratings over the last three months, with 10 analysts offering diverse opinions. The average 12-month price target is $308.7, with a high of $373.00 and a low of $239.00, marking a 3.1% decrease from the previous average. Recent actions by analysts include maintaining, raising, and lowering ratings and price targets. Biogen's financials show a revenue growth rate of 0.87%, a net margin of -2.69%, an ROE of -0.47%, an ROA of -0.26%, and a debt-to-equity ratio of 0.53.

Portfolio Pulse from Benzinga Insights

January 24, 2024 | 1:00 pm

AVXL

Anavex Life Sciences announced a peer-reviewed publication in Clinical Pharmacology in Drug Development, reporting findings from the ANAVEX 3-71 first-in-human study. The study met its safety objectives, indicating a positive outcome for the company's drug development process.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 12:35 pm

MOB

Mobilicom's ICE Cybersecurity system, an AI-based software for drones, has been selected by Israel's Ministry of Defense for its small-sized drone program. The initial order was completed in January 2024, with expectations for further orders and deliveries in Q2 2024 and onwards.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 12:10 pm